Table 1.

Age, gender, Braak stages, PMD, and use of brains in the study^a

Case no.	Thal Aβ phase	Braak stage	CERAD	AD neuropathologic change	Age (yr)	Gender	PMD (h)	Analysis
1	0	0	−	No	68	M	54	WB/IF/ELISA
2	1	0	−	Low	78	F	34	WB/IF/ELISA
3	0	0	−	No	73	M	25	WB/IF/ELISA
4	0	0	−	No	63	M	30	ELISA
5	1	0	−	Low	75	M	20	ELISA
6	0	0	−	No	59	F	19	ELISA
7	1	1	−	Low	73	F	16	WB/IF/ELISA
8	1	1	−	Low	72	M	17	ELISA
9	1	2	A	Low	83	F	19	WB/IF/ELISA
10	1	2	−	Low	74	F	45	WB/IF/ELISA
11	2	2	A	Low	87	M	8	ELISA
12	1	2	−	Low	78	F	23	ELISA
13	0	3	−	No	88	F	22	WB/IF/ELISA
14	2	3	−	Low	89	F	34	WB/IF/ELISA
15	0	3	−	No	81	M	43	WB/IF/ELISA
16	2	3	A	Low	84	F	8	ELISA
17	3	3	A	Intermediate	91	M	12	ELISA
18	4	3	C	Intermediate	79	M	13	ELISA
19	4	6	C	High	83	F	12	WB/IF/ELISA
20	5	6	C	High	86	F	5	WB/IF/ELISA
21	5	6	C	High	76	F	37	WB/IF/ELISA
22	4	6	C	High	72	F	27	ELISA
23	5	6	B	High	77	F	30	ELISA
24	4	6	C	High	59	M	44	ELISA

^aPMD, Postmortem delay; WB, Western blotting; IF, immunofluorescence.